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Received March 26, 2015; accepted November 4, 2015AbstractBackground: Percutaneous coronary intervention (PCI) has emerged as an alternative treatment to coronary artery bypass grafting (CABG) for
unprotected left main (LM) coronary artery disease, but the results of both treatments are less clear in real-world practice. We aimed to assess the
long-term outcomes of unprotected LM disease treated with CABG or PCI with stenting in high-risk population from a single center.
Methods: We collected 478 consecutive patients with unprotected LM disease (PCI/CABG: 208/270; mean age: 70 ± 11 years; 85% male), and
252 patients were considered to be at high risk (European System for Cardiac Operative Risk Evaluation 6). The median follow-up was
4.3 years (interquartile range: 2.7e6.5 years).
Results: All-cause death (PCI/CABG: 27.4%/31.5%; p ¼ 0.36) and all-cause death/myocardial infarction (MI)/stroke (PCI/CABG: 30.8%/
35.9%; p ¼ 0.49) were comparable between the two groups, whereas the repeat revascularization rate was significantly higher in the PCI group
(PCI/CABG: 22.6%/11.0%; p < 0.01). These results remained similar after adjustment with the propensity score. Notably, CABG tended to be
associated with higher periprocedural mortality (adjusted p ¼ 0.08) and long-term stroke (adjusted p ¼ 0.05), while PCI was associated with
higher long-term MI (adjusted p ¼ 0.09). Analyses of the diabetic subgroup (PCI/CABG: 98/124) yielded similar results.
Conclusion: PCI was a comparable alternative to CABG for high-risk patients with unprotected LM disease in terms of long-term risks of all-
cause death/MI/stroke, but with a significantly higher repeat revascularization rate.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction coronary artery disease, percutaneous coronary interventionAlthough coronary artery bypass grafting (CABG) remains
the reference of treatment for unprotected left main (LM)Conflicts of interest: The authors declare that they have no conflicts of interest
related to the subject matter or materials discussed in this article.
* Corresponding author. Dr. Chiao-Po Hsu, Division of Cardiovascular
Surgery, Department of Surgery, Taipei Veterans General Hospital, 201, Sec-
tion 2, Shih-Pai Road, Taipei 112, Taiwan, ROC.
E-mail address: hsucp@vghtpe.gov.tw (C.-P. Hsu).
http://dx.doi.org/10.1016/j.jcma.2016.01.005
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).(PCI) with stenting, especially using the drug-eluting stent
(DES), has emerged as an alternative treatment with accept-
able short- and long-term clinical outcomes in recent stud-
ies.1e5 Although treatment of LM disease with PCI seemed to
have a similar long-term mortality rate to that with CABG,
PCI was consistently associated with a higher rate of repeated
revascularization than CABG, even with the use of DESs.6e13
Furthermore, a recent meta-analysis comparing the long-term
outcomes of PCI with CABG showed that the patients with
LM disease treated with PCI suffered from less strokes, whilesevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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myocardial infarction (MI).14 Therefore, considering the sur-
gical risk, the potentially troublesome in-stent restenosis and
late/very late stent thrombosis, as well as the patient's and
physician's preferences, the choice of treatment in real-world
daily practice may sometimes be difficult. In this study, we
aimed to assess the long-term clinical outcomes of LM disease
treated with PCI with stenting or CABG in a real-world high-
risk population from a single center.
2. Methods
This study was a retrospective observational study and
included 478 consecutive patients with unprotected LM cor-
onary artery stenosis (>50% narrowing) undergoing PCI or
CABG at Taipei Veterans General Hospital, Taipei, Taiwan
from January 2004 to December 2010. Unprotected LM dis-
ease was defined as significant LM coronary artery stenosis
without patent coronary artery bypass graft to the left anterior
descending or left circumflex artery. Patients with acute cor-
onary syndrome with cardiogenic shock and acute ST segment
elevation MI with totally occluded LM coronary artery as the
culprit lesion were excluded. Patients who underwent
concomitant valvular or aortic surgery were also excluded.
The decision to perform PCI or CABG depended on the pa-
tient's or physician's preference or surgical/interventional risk
profile. The surgical risk of the patient was evaluated ac-
cording to the European System for Cardiac Operative Risk
Evaluation (EuroSCORE),15 which was computed by two
experienced cardiologists who were unaware of the clinical
course of patients. Patients with a EuroSCORE of 6 were
considered to be at high surgical risk.
In the CABG group, CABG was performed with the stan-
dard bypass procedure. On-pump beating heart surgery was
performed in high-risk patients not suitable for aortic clamp-
ing. The left internal mammary artery was harvested to bypass
the left anterior descending coronary artery in all possible
cases. In patients younger than 60 years, radial artery graft was
considered. Aspirin or and/or clopidogrel for life-long use was
prescribed as soon as possible after the surgery. Complete
revascularization was attempted whenever possible using
arterial conduits or saphenous vein grafts.
In the PCI group, patients underwent PCI due to either the
patient's or the physician's preference, or due to a high surgical
risk. PCI and ventriculography were performed by the stan-
dard procedure as described before.16 Predilatation with a
balloon catheter was performed in all cases. For most LM
lesions involving distal bifurcation, stenting across the bifur-
cation toward the left anterior descending artery (crossover
technique) was attempted, followed by provisional stenting of
the left circumflex artery (T-stenting or culotte stenting) if
there was residual stenosis or dissection over the orifice of the
left circumflex artery. Postdilatation with the kissing balloon
technique was attempted except in cases with technique dif-
ficulty or small non-dominant left circumflex artery. Debulk-
ing by means of a rotablator was used only for highly calcified
lesions, and the use of intravascular ultrasound andglycoprotein IIb/IIIa receptor antagonist were at the discretion
of the interventional operators. After the procedure, all pa-
tients received aspirin (100 mg/d) indefinitely and clopidogrel
(300 mg loading dose, then 75 mg/d) or ticlopidine (500 mg
loading dose, then 250 mg twice a day) for at least 1 month
[bare metal stent (BMS)] or 12 months (DES). Medications
for treatment of angina pectoris (calcium channel blockers,
beta-blockers, and nitrates) were continued.
All patients were followed up completely without any cases
being lost to follow-up. For all patients undergoing PCI or
CABG, follow-up angiography was performed only when
there were ischemic symptoms or signs and/or noninvasive
evidence of ischemia. The clinical follow-up data were
collected during scheduled monthly clinic evaluations or
through direct telephone contact for all-cause death and first-
ever major adverse cardiovascular cerebrovascular event
(MACCE), which was defined as all-cause death, MI, stroke,
and clinically driven repeat revascularization. MI was defined
as the presence of significant new Q waves in at least two
electrocardiographic leads or the presence of symptoms
compatible with MI associated with an increase in creatine
kinase-MB fraction three or more times the upper limit of the
reference range. Stroke with neurological deficit was diag-
nosed by a neurologist on the basis of an imaging study. Stent
thrombosis occurrence was classified as definite, probable, or
possible according to the Academic Research Consortium
criteria,17 and was considered as acute (within 24 hours),
subacute (within 30 days), late (after 30 days and within
12 months), or very late (after 1 year). The study protocol was
approved by the Institutional Review Board at Taipei Veterans
General Hospital, and informed written consent was obtained
from each participant.
All continuous variables were presented as
mean ± standard deviation, and categorical variables as
numbers and percentages. The differences of continuous data
between the PCI and CABG groups were compared by two-
sample t test. Categorical data between the two groups were
compared by means of Chi-square test or Fisher's exact test.
Multivariable Cox regression analysis was performed to
determine the independent predictors of long-term clinical
outcomes. Hazard ratios (HR) and 95% confidence intervals
(CI) were calculated. To reduce the effect of treatment se-
lection bias and compensate for potential confounding factors
in this observational study, we calculated the propensity score
using multiple logistic regression analysis, incorporating all
the variables shown in Table 1. Cox regression analysis
adjusted with the propensity score was performed in all pa-
tients. A p value <0.05 was considered to be statistically
significant. SPSS version 17.0 (SPSS Inc., Chicago, IL, USA)
software package was used for statistical analysis.
3. Results3.1. Patient characteristicsFrom January 2004 to December 2010, we collected 478
consecutive patients with unprotected LM coronary artery
Table 1
Baseline characteristics of patients treated with PCI and CABG.
PCI
(n ¼ 208)
CABG
(n ¼ 270)
p Adjusted
p valuea
Age (y) 70 ± 12 69 ± 11 0.26 0.94
Gender
(M/F)
175/33 231/39 0.70 0.99
Hypertension 163 (78) 223 (83) 0.29 0.94
Diabetes 98 (47) 124 (46) 0.85 0.96
Hypercholesterolemia 112 (54) 135 (50) 0.41 0.95
Smoking 104 (50) 180 (67) <0.01 0.89
Peripheral
artery disease
27 (13) 42 (16) 0.44 0.46
Clinical
presentation as ACS
103 (50) 146 (54) 0.36 0.96
LVEF (%) 49 ± 12 49 ± 12 0.66 0.99
Creatinine
(mg/dL)
1.8 ± 2.0 1.7 ± 2.0 0.75 0.99
eGFR
(mL/min/1.73 m2)
67 ± 32 66 ± 30 0.84 0.89
Chronic
kidney disease
84 (40) 101 (37) 0.57 0.38
EuroSCORE 7.1 ± 5.1 6.4 ± 4.0 0.13 0.13
EuroSCORE 6 116 (56) 136 (50) 0.27 0.32
Medications
ACE
inhibitors/ARB
121 (58.2) 176 (65.2) 0.13 0.30
Beta-blocker 125 (60.1) 174 (64.4) 0.34 0.57
CCB 110 (52.9) 181 (67.0) <0.01 <0.01
Statins 129 (62.0) 167 (61.9) 1.00 0.29
Antiplatelets 190 (91.3) 256 (94.8) 0.14 0.11
Diuretic 65 (31.2) 107 (39.6) 0.07 0.41
Angiographic and procedure characteristics
LM bifurcation involved 146 (70) 207 (77) 0.12 0.94
Right coronary
artery involved
117 (56) 230 (85) <0.01 0.93
Extent of diseased vessel
LM only 9 (4.3) 5 (1.9)
LM plus 1-vessel 44 (21) 13 (4.8)
LM plus 2-vessel 64 (31) 49 (18)
LM plus 3-vessel 91 (44) 203 (75) <0.01 0.96
Use of drug
eluting stent
131 (63)
Sirolimus 44 (34)
Paclitaxel 40 (31)
Everolimus 25 (19)
Zotalimus 22 (17)
Use of intravascular
ultrasound
43 (21)
Use of rotablator 15 (7.2)
Data are presented as n (%) or mean ± standard deviation, unless otherwise
indicated.
ACE ¼ angiotensin-converting enzyme; ACS ¼ acute coronary syndrome;
ARB ¼ angiotensin receptor blocker; CABG ¼ coronary artery bypass
grafting; CCB ¼ calcium channel blocker; eGFR ¼ estimated glomerular
filtration fraction; EuroSCORE ¼ European System for Cardiac Operative
Risk Evaluation; F ¼ female; LM ¼ left main; LVEF ¼ left ventricular
ejection fraction; M ¼ male; PCI ¼ percutaneous coronary intervention.
a Propensity score adjusted.
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CABG. The mean age of the population was 70 ± 11 years,
with male (85%) predominance. More than half of patients
(249 patients, 52%) presented with non-ST segment elevation
acute coronary syndrome. Furthermore, 222 patients (46%)and 185 patients (39%) suffered from diabetes and chronic
kidney disease (estimated glomerular filtration rate <60 mL/
min per 1.73 m2) respectively, and 112 patients (23%) pre-
sented with left ventricular ejection fraction <40%. In
particular, 252 patients (53%) with an additive EuroSCORE of
6 were considered to be at high risk. These features sug-
gested that these study patients belonged to a higher-risk
population. The baseline characteristics of the PCI and
CABG groups are summarized in Table 1. There were no
significant differences in atherosclerotic risk factors between
the PCI and CABG groups, except for a higher prevalence of
smoking history in patients undergoing CABG. By contrast,
the patients undergoing CABG had more complex coronary
anatomy, including more triple-vessel disease and more
involvement of the right coronary artery (Table 1). Finally,
there were no significant differences of medication between
both groups except that more CABG patients received calcium
channel blockers ( p < 0.01, Table 1).
In the PCI group, DES was used in 131 patients (63%),
with most patients using first-generation DES (sirolimus-
eluting stent and paclitaxel-eluting stent, 64%). The cross-over
technique (n ¼ 166) was used in 107 patients (73.3%) with
distal bifurcation involvement. In patients treated with more
than one stent, T-stenting with final kissing balloon post-
dilatation (24 patients, 16.4%) was used more often than
crush/minicrash (4.1%) and culotte stenting (6.2%). Intravas-
cular ultrasound and rotablation were applied in 43 (20.7%)
and 15 (7.2%) patients, respectively (Table 1).
In the CABG group, only 12 patients (4.4%) underwent off-
pump surgery, and 220 (81.5%) patients received at least one
arterial conduit; the others received vein grafts due to poor
quality of LIMA or urgent surgery. The mean numbers of grafts
were 0.9 ± 0.5 (arterial grafts) and 2.3 ± 0.8 (venous grafts).
Re-do sternotomy was performed in two patients (0.7%). The
medication used for both groups is also shown in Table 1.3.2. Thirty-day and long-term outcomesTable 2 summarizes 30-day and long-term clinical out-
comes after treatment with PCI or CABG. Within the 30-day
period after index procedure, CABG appeared to be associated
with significantly more deaths and MACCE. By contrast, one
case of definite subacute stent thrombosis (14 days after BMS
stenting) and two cases of probable acute or subacute stent
thrombosis occurred in the PCI group (1 day after DES
stenting and 1 week after BMS stenting, respectively) ac-
cording to the definition of Academic Research Consortium
criteria, and all three lead to cardiovascular deaths.
As for the long-term outcomes, the median follow-up
period was 4.3 years (25e75%; range: 2.7e6.5 years). Dur-
ing the follow-up period, there were 142 all-cause deaths
(29.7%) and 205 cumulative MACCE (42.9%), which also
included 35 nonfatal MI (7.3%), 18 stroke (3.8%), and 78
repeat revascularization (16.3%; Table 2). The nonadjusted
long-term rates of all-cause death (nonadjusted p ¼ 0.36), all-
cause death/MI/stroke (nonadjusted p ¼ 0.49), and MACCE
(nonadjusted p ¼ 0.71) were comparable between the PCI and
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rate was significantly higher in the PCI group (nonadjusted
p < 0.01; Table 2). There were two cases of probable late stent
thrombosis that occurred at 180 days and 266 days after PCI,
respectively (cumulative definite/probable stent thrombosis
cases: 5, 2.4%). Both patients underwent LM PCI using BMS,
and these episodes resulted in sudden death. There was no case
with very late stent thrombosis.
We analyzed the long-term clinical outcomes for the dia-
betic subgroup. Comparing to nondiabetic patients, the pa-
tients with diabetes were associated with significantly higher
risk for all-cause death, all-cause death/MI/stroke, and
MACCE ( p ¼ 0.04, p ¼ 0.02, and p ¼ 0.005, respectively)
and had a trend toward increased risk of repeat revasculari-
zation ( p ¼ 0.07). Analyses of the diabetic subgroup (n ¼ 222;
PCI: n ¼ 98; CABG: n ¼ 124) yielded results similar to those
of the overall cohort, with comparable EuroSCORE, all-cause
death rate, and MACCE rate between the PCI and CABG
groups, and a significantly higher repeat revascularization rate
in the PCI group (Table 3).
Table 4 shows the result of multivariate Cox regression
analysis of long-term clinical outcomes. The treatment with
CABG remained an independent protective factor against
repeat revascularization (adjusted HR: 0.40; 95% CI:
0.25e0.63; p < 0.01; Table 4).3.3. Propensity score-adjusted clinical outcomesThere were no significant differences in clinical and
angiographic characteristics between the PCI and CABG
groups after adjustment with the propensity score (Table 1).Table 2
Thirty-day and cumulative long-term outcomes.
PCI
(n ¼ 208)
CABG
(n ¼ 270)
p Adjusted
p valuea
30-d outcomes
All-cause
death
3 (1.4) 14 (5.2) 0.04 0.08
MI 1 (0.5) 1 (0.4) 0.85 0.49
Repeat revascularization 0 (0.0) 1 (0.4) 1.0 1.0
Stroke 1 (0.5) 5 (1.9) 0.22 0.34
All-cause death/MI/stroke 4 (1.9) 18 (6.7) 0.02 0.05
MACCE 4 (1.9) 18 (6.7) 0.02 0.05
Definite/probable stent thrombosis 3 (1.4)
Long-term outcomes
All-cause death 57 (27.4) 85 (31.5) 0.36 0.80
MI 17 (8.2) 18 (6.7) 0.45 0.09
Repeat revascularization 47 (22.6) 31 (11.0) <0.01 <0.01
Stroke 4 (1.9) 14 (5.2) 0.09 0.05
All-cause death/MI/stroke 64 (30.8) 97 (35.9) 0.49 0.88
MACCE 91 (43.8) 114 (42.2) 0.71 0.13
Definite/probable stent thrombosis 5 (2.4)
Data are presented as n (%).
CABG ¼ coronary artery bypass grafting; MACCE ¼ major adverse cardiac
and cerebrovascular event, including all-cause death, myocardial infarction,
stroke and repeat revascularization; MI ¼ myocardial infarction;
PCI ¼ percutaneous coronary intervention.
a Propensity score adjusted.After adjustment with the propensity score, Fig. 1 shows the
adjusted cumulative incidence curves of all-cause death, all-
cause death/MI/stroke, MACCE, and repeat revascularization
based on the revascularization procedure. There were no sig-
nificant differences in the adjusted rate of long-term all-cause
death, all-cause death/MI/stroke, and MACCE between the
PCI and CABG groups, whereas the rate of adjusted repeat
revascularization remained significantly higher in the PCI
group (adjusted p < 0.01). Notably, CABG tended to be
associated with higher periprocedural mortality (adjusted
p ¼ 0.08) and long-term stroke (adjusted p ¼ 0.05), while PCI
tended to be associated with a higher risk of long-term MI
(adjusted p ¼ 0.09).
4. Discussion
The results of this study showed that, in a cohort with
unprotected LM disease, the long-term risks of all-cause
death/MI/stroke and MACCE were similar in the PCI and
CABG groups during a median follow-up period of 4.3 years.
By contrast, the rate of long-term repeat revascularization was
significantly higher in the PCI group than in the CABG group.
Subgroup analysis of diabetic patients yielded results similar
to those of the overall cohort.
As CABG may be associated with a higher rate of peri-
procedural MI and stroke and potential long-term advantage,
studies with limited follow-up periods may not be appropriate
to compare the clinical outcomes of CABG and PCI. Park
et al10 have reported a single-center experience in a 10-year
follow-up cohort of patients with LM disease treated with
BMS and CABG, and a 5-year follow-up cohort of patients
with LM disease treated with DES and CABG. They found
that there were no significant differences in the adjusted risk of
death and the composite of death, MI, or stroke between BMS
and CABG or between DES and CABG. By contrast, the rate
of TVR was consistently higher in the BMS or DES groupTable 3
Cumulative long-term outcomes in LM patients with and without diabetes.
With diabetes Without diabetes
PCI
(n ¼ 98)
CABG
(n ¼ 124)
pa PCI
(n ¼ 110)
CABG
(n ¼ 146)
pa
EuroSCORE 7.5 ± 5.3 6.9 ± 4.3 0.32 6.7 ± 4.8 6.1 ± 3.7 0.26
All-cause death 31 (31.6) 45 (36.3) 0.59 26 (23.6) 40 (27.4) 0.87
MI 9 (9.2) 8 (6.5) 0.16 8 (7.3) 10 (6.8) 0.14
Repeat
revascularization
25 (25.5) 17 (13.7) 0.01 22 (20.0) 14 (9.6) <0.01
Stroke 3 (3.1) 8 (6.5) 0.26 1 (0.9) 6 (4.1) 0.10
All-cause
death/MI/stroke
35 (35.7) 51 (41.1) 0.80 29 (26.4) 46 (31.5) 0.99
MACCE 48 (49.0) 62 (50.0) 0.53 43 (39.1) 52 (35.6) 0.14
Data are presented as n (%) or mean ± standard deviation.
CABG ¼ coronary artery bypass grafting; EuroSCORE ¼ European System
for Cardiac Operative Risk Evaluation; LM ¼ left main coronary artery dis-
ease; MACCE ¼ major adverse cardiac and cerebrovascular event, included
all-cause death, myocardial infarction, stroke and repeat revascularization;
MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention.
a Propensity score adjusted.
Table 4
Multivariate Cox regression analysis for all-cause death and all-cause death/
MI/stroke, and for MACCE and repeat revascularization.
Variables All-cause death All cause death/MI/stroke
HR (95% CI) p HR (95% CI) p
Age 1.04 (1.02e1.05) <0.01 1.04 (1.02e1.06) <0.01
ACS 1.53 (1.06e2.20) 0.02 1.79 (1.27e2.54) <0.01
LVEF 0.98 (0.97e0.99) <0.01 0.98 (0.97e1.00) <0.01
DM d d 1.40 (1.02e1.92) 0.04
Cr 1.21 (1.41e1.28) <0.01 1.17 (1.10e1.24) <0.01
CCB 0.57 (0.41e0.80) <0.01 0.59 (0.43e0.80) <0.01
MACCE Repeat revascularization
HR (95% CI) p HR (95% CI) p
Age 1.02 (1.01e1.03) <0.01 d d
ACS 1.60 (1.19e2.16) <0.01 1.96 (1.24e3.12) <0.01
LVEF 0.99 (0.98e1.00) 0.01 d d
DM 1.44 (1.09e1.91) 0.01 d d
Cr 1.13 (1.07e1.20) <0.01 d d
CCB 0.61 (0.47e0.81) <0.01 d d
PCI/CABG d d 0.40 (0.25e0.63) <0.01
ACS ¼ acute coronary syndrome; CABG ¼ coronary artery bypass grafting;
CCB ¼ calcium channel blocker; CI ¼ confidence interval; Cr ¼ creatinine;
DM ¼ diabetes mellitus; HR ¼ hazard ratio; LVEF ¼ left ventricular ejection
fraction; MACCE ¼ major adverse cardiac and cerebrovascular event,
included all-cause death, myocardial infarction, stroke and repeat revascular-
ization; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary
intervention.
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year result of the LM subgroup in the Synergy between
Percutaneous Coronary Intervention with Taxus and Cardiac
Surgery (SYNTAX) trial, no differences in overall mortality
and MACCE were found between the PCI and CABG groups.
Nevertheless, LM patients receiving PCI had a lower stroke
rate and higher revascularization rate compared with those
receiving CABG.18 Although our study patients were enrolled
from daily practice of a single center and were at higher
surgical risk compared with previous studies (mean age
~70 years, nearly half of the patients had diabetes,
EuroSCORE  6, and clinical presentation as acute coronary
syndrome), our study's results remained consistent with those
of the previous studies, although with higher rates of adverse
clinical outcomes (e.g., PCI vs. CABG: all-cause death: 27.4%
vs. 31.5%; MACCE: 43.8% vs. 42.2%, compared with those of
the SYNTAX 5-year results: all-cause death: 12.8% vs. 14.6%;
MACCE: 36.9% vs. 31.0%). Thus, our study might expand the
findings of the previous randomized trial to the real-world
high-risk population with unprotected LM disease and might
be beneficial in the choice of treatment.
The repeat revascularization rate in our PCI patients
remained significantly higher than that in the CABG group,
even with propensity score adjustment, which is in accordance
with those previous studies,6e13 although the overall revas-
cularization rate was higher in our studies. In particular, the
revascularization rate was much higher in our CABG patients
in comparison with previous studies,6e13 but it was compa-
rable with that of the SYNTAX trial 5-year result.18 Both a
higher surgical risk profile and reduced use of arterial conduits
in our patients (81.5%) compared to previous studies might bethe contributing factors.10,11 By contrast, as the follow-up
angiography was done only by clinical indications and the
angiographic follow-up rate was relatively low, especially in
the CABG group, the restenosis rate in the PCI group and
asymptomatic graft failure might be underestimated.
A recent meta-analysis compared the long-term clinical
outcomes of PCI versus CABG for unprotected LM disease,
and found that the CABG patients had fewer occurrences of
MI but a higher risk of stroke.14 Although the significantly
increased risk of stroke with CABG at 1 year in the global
SYNTAX cohort did not become more significant at 5 years,
probably due to a late catch-up of stroke in the PCI arm,19 the
stroke risk remained significantly higher in the LM subgroup
of the CABG group at 5 years ( p ¼ 0.03).18 Our results were
similar, showing that there was a trend toward less strokes and
a higher MI rate (propensity score-adjusted p ¼ 0.05 and
p ¼ 0.09, respectively) in the PCI group. Nevertheless, our
findings must be interpreted with caution due to the limited
patient number and observational nature of our study, and
further large studies may be needed to elucidate these
important issues.
Percutaneous revascularization intervention in diabetic pa-
tients remains challenging, and the large Future Revasculari-
zation Evaluation in Patients with Diabetes Mellitus: Optimal
Management of Multivessel Disease (FREEDOM) trial
demonstrated that long-term all-cause/cardiovascular death
and MI occurred more frequently in patients treated with
PCI.20 However, LM patients were excluded from the
FREEDOM trial. Although diabetic patients in our study had
overall worse outcomes compared with nondiabetic patients,
all-cause mortality and MACCE rates were comparable, and
repeat revascularization was higher in diabetic patients un-
dergoing CABG or PCI, which was similar to the results for
the overall study population. These findings were in line with
the diabetic subgroup analyses in the Revascularization for
Unprotected Left Main Coronary Artery Stenosis: Comparison
of Percutaneous Coronary Angioplasty Versus Surgical
Revascularization registry and the SYNTAX 5-year result, but
were different from those of other observational studies.18,21,22
Different demographic/surgical risk profiles and follow-up
periods might be possible explanations, and further large-
scale studies may be warranted for diabetic patients with un-
protected LM disease.
This study has several limitations. First, this study was
retrospective and observational, with a relatively small cohort.
Furthermore, our study findings were derived mainly from a
single-center high-surgical-risk cohort. Although we used a
propensity score-adjusted analysis to minimize the selection
bias, potential confounding bias might have remained in our
study results. Second, due to the long period of study enroll-
ment from 2004 to 2010, a significant heterogeneity in treat-
ment/stenting/surgical strategy could exist. Third, the
preference of medication prescribed for patients is different
between cardiologists and cardiac surgeons, which might make
interpretation of the results more difficult. Furthermore, nearly
half of the patients in the present study received BMS stenting,
and most of the DESs used were the first-generation DESs. Our
Fig. 1. Cumulative incidence of (A) all-cause death, (B) all-cause death/MI/stroke, (C) MACCE, and (D) repeat revascularization in the PCI and CABG groups.
The curves were constructed with Cox regression analyses adjusted for propensity score. CABG ¼ coronary artery bypass grafting; MACCE ¼ major adverse
cardiac and cerebrovascular event, included all-cause death, myocardial infarction, stroke and repeat revascularization; MI ¼ myocardial infarction;
PCI ¼ percutaneous coronary intervention.
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with newer-generation DESs; the EXCEL trial, which
compared the safety and efficacy of everolimus-eluting stent
with CABG in selected patients with unprotected LM disease,
may be expected to give more information. Fourth, as
mentioned above, the angiographic follow-up rate of our
population was relatively low, so incomplete angiographic
follow-up-related potential bias might have a substantial
impact on the long-term clinical outcomes in both groups.
In conclusion, in the real-world practice of patients with
unprotected LM disease in a single center, we found that PCI
was a comparable alternative to CABG in terms of long-term
risks of all-cause death/MI/stroke and MACCE. In contrast,
the rate of long-term repeat revascularization remained
significantly higher in the PCI group than in the CABG group.
Diabetic subgroup analysis yielded similar results.
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